DUONEB

Clinical safety rating: caution

Comprehensive clinical and safety monograph for DUONEB (DUONEB).

How it works

DUONEB is a combination of ipratropium bromide (anticholinergic) and albuterol sulfate (beta-2 adrenergic agonist). Ipratropium inhibits muscarinic acetylcholine receptors in bronchial smooth muscle, reducing vagal tone and bronchodilation. Albuterol stimulates beta-2 adrenergic receptors, leading to relaxation of bronchial smooth muscle.

What the body does with it

Metabolism	Ipratropium is minimally absorbed and partially metabolized by ester hydrolysis to inactive metabolites. Albuterol is primarily metabolized by sulfation (not CYP450) to albuterol 4'-O-sulfate.
Excretion	DuoNeb (ipratropium bromide/albuterol sulfate) is a fixed-dose combination. Ipratropium: 90% excreted unchanged in feces (biliary), <10% renal. Albuterol: 60-70% renal as unchanged drug and metabolites (sulfate conjugate), 30-40% fecal.
Half-life	Ipratropium: terminal half-life ~2 hours (range 1.5-4 hours). Albuterol: terminal half-life 3.8-6 hours (mean ~4.6 hours). Clinical context: Both contribute to bronchodilation lasting 4-6 hours.
Protein binding	Ipratropium: 0-9% bound to plasma proteins. Albuterol: 50-60% bound, primarily to albumin.
Volume of Distribution	Ipratropium: Vd ~4.6 L/kg (large, extensive tissue distribution). Albuterol: Vd ~2.3 L/kg (distributes into tissues, including placenta and breast milk).
Bioavailability	Inhalation: Ipratropium 7-28% (mean 18%); Albuterol 10-20%. Oral (swallowed): Ipratropium <1%; Albuterol ~50% but not used clinically.
Onset of Action	Inhalation: Ipratropium onset 15-30 minutes (peak 1-2 hours); Albuterol onset 5-15 minutes (peak 30-90 minutes).
Duration of Action	4-6 hours for bronchodilation. Clinical note: Combination provides additive effect with longer duration than albuterol alone in some patients.

Classification & Brands

Dosing & administration

1-2 vials (2.5 mg ipratropium bromide/2.5 mg albuterol sulfate per 3 mL vial) via nebulization every 6 hours as needed; maximum 6 vials per day.

Dosage form	SOLUTION
Renal impairment	No adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, data insufficient but caution advised; consider monitoring for adverse effects.
Liver impairment	No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential for increased systemic exposure.
Pediatric use	Children <12 years: not recommended; children ≥12 years: same as adult dosing.
Geriatric use	No specific dose adjustment; use lowest effective dose due to potential for increased anticholinergic side effects and reduced renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for DUONEB (DUONEB).

Breastfeeding	Albuterol is excreted into breast milk; estimated infant dose 0.1-0.2% of maternal weight-adjusted dose; ipratropium is poorly absorbed and unlikely to affect infant. M/P ratio: not established for combination; use caution.
Teratogenic Risk	Ipratropium and albuterol sulfate are both Pregnancy Category C. Ipratropium: No teratogenic effects in animal studies; insufficient human data; risk cannot be ruled out. Albuterol: Associated with increased fetal heart rate and hypoglycemia in newborns when used in preterm labor; no evidence of teratogenicity in humans at therapeutic doses. Use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["History of hypersensitivity to ipratropium, albuterol, or any component (including atropine or derivatives)."]

Clinical Precautions

Precautions

["Paradoxical bronchospasm may occur; discontinue immediately if occurs.","Cardiovascular effects (increased heart rate, blood pressure, ECG changes) with albuterol; use with caution in patients with cardiovascular disorders.","Immediate hypersensitivity reactions (urticaria, angioedema, rash) may occur.","Albuterol may cause hypokalemia when used with diuretics or steroids.","Not indicated for acute deterioration of COPD; single-strength formulation is not for acute attacks."]

Clinical Tips & Counseling

Drug interactions

Loading safety data…

DUONEB

Clinical safety rating: caution

Comprehensive clinical and safety monograph for DUONEB (DUONEB).

How it works

What the body does with it

Metabolism	Ipratropium is minimally absorbed and partially metabolized by ester hydrolysis to inactive metabolites. Albuterol is primarily metabolized by sulfation (not CYP450) to albuterol 4'-O-sulfate.
Excretion	DuoNeb (ipratropium bromide/albuterol sulfate) is a fixed-dose combination. Ipratropium: 90% excreted unchanged in feces (biliary), <10% renal. Albuterol: 60-70% renal as unchanged drug and metabolites (sulfate conjugate), 30-40% fecal.
Half-life	Ipratropium: terminal half-life ~2 hours (range 1.5-4 hours). Albuterol: terminal half-life 3.8-6 hours (mean ~4.6 hours). Clinical context: Both contribute to bronchodilation lasting 4-6 hours.
Protein binding	Ipratropium: 0-9% bound to plasma proteins. Albuterol: 50-60% bound, primarily to albumin.
Volume of Distribution	Ipratropium: Vd ~4.6 L/kg (large, extensive tissue distribution). Albuterol: Vd ~2.3 L/kg (distributes into tissues, including placenta and breast milk).
Bioavailability	Inhalation: Ipratropium 7-28% (mean 18%); Albuterol 10-20%. Oral (swallowed): Ipratropium <1%; Albuterol ~50% but not used clinically.
Onset of Action	Inhalation: Ipratropium onset 15-30 minutes (peak 1-2 hours); Albuterol onset 5-15 minutes (peak 30-90 minutes).
Duration of Action	4-6 hours for bronchodilation. Clinical note: Combination provides additive effect with longer duration than albuterol alone in some patients.

Classification & Brands

Dosing & administration

1-2 vials (2.5 mg ipratropium bromide/2.5 mg albuterol sulfate per 3 mL vial) via nebulization every 6 hours as needed; maximum 6 vials per day.

Dosage form	SOLUTION
Renal impairment	No adjustment required for GFR ≥30 mL/min; for GFR <30 mL/min, data insufficient but caution advised; consider monitoring for adverse effects.
Liver impairment	No specific guidelines; use with caution in severe hepatic impairment (Child-Pugh C) due to potential for increased systemic exposure.
Pediatric use	Children <12 years: not recommended; children ≥12 years: same as adult dosing.
Geriatric use	No specific dose adjustment; use lowest effective dose due to potential for increased anticholinergic side effects and reduced renal function.

Use during pregnancy

1st trimester	Consult provider
2nd trimester	Consult provider
3rd trimester	Consult provider

Clinical note

Comprehensive clinical and safety monograph for DUONEB (DUONEB).

Breastfeeding	Albuterol is excreted into breast milk; estimated infant dose 0.1-0.2% of maternal weight-adjusted dose; ipratropium is poorly absorbed and unlikely to affect infant. M/P ratio: not established for combination; use caution.
Teratogenic Risk	Ipratropium and albuterol sulfate are both Pregnancy Category C. Ipratropium: No teratogenic effects in animal studies; insufficient human data; risk cannot be ruled out. Albuterol: Associated with increased fetal heart rate and hypoglycemia in newborns when used in preterm labor; no evidence of teratogenicity in humans at therapeutic doses. Use only if clearly needed.

Warnings & precautions

■ FDA Black Box Warning

No FDA black box warning.

Side Effect Profile

Serious Effects

Absolute Contraindications

["History of hypersensitivity to ipratropium, albuterol, or any component (including atropine or derivatives)."]